Search

Your search keyword '"Tumors -- Drug therapy -- Genetic aspects"' showing total 9 results
Start Over Descriptor "Tumors -- Drug therapy -- Genetic aspects" Topic united states. food and drug administration
9 results on '"Tumors -- Drug therapy -- Genetic aspects"'

1. Senhwa Biosciences seeks US FDA and Health Canada approvals for CX-5461 to treat solid tumors with BRCA2 or PALB2 mutations

Subjects
United States. Food and Drug Administration, Cancer treatment, Talazoparib, Cancer research -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Drug approval, Pharmaceuticals and cosmetics industries
Abstract

Senhwa Biosciences Inc, a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced that it has submitted multiple Investigational New Drug (IND) [...]

Published
2020

2. Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Subjects
United States. Food and Drug Administration, Cancer treatment, Talazoparib, Cancer research -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, General interest, News, opinion and commentary
Abstract

TAIPEI: Senhwa Biosciences, Inc. has issued the following news release: Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment [...]

Published
2020

3. Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Subjects
United States. Food and Drug Administration, Cancer treatment, Talazoparib, Cancer research -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Business, international, Law
Abstract

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has submitted multiple Investigational [...]

Published
2020

4. Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Subjects
United States. Food and Drug Administration, Oncology, Experimental -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Cancer -- Care and treatment -- Research, Business, News, opinion and commentary
Abstract

TAIPEI and SAN DIEGO, Nov. 25, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of [...]

Published
2020

5. PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Subjects
United States. Food and Drug Administration, Cancer treatment, Tumor proteins -- Genetic aspects -- Drug therapy, Tumors -- Drug therapy -- Genetic aspects, Cancer patients -- Drug therapy, Drug approval, Business, international, Law
Abstract

(GlobeNewswire) - PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced that the U.S. Food [...]

Published
2020

6. PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Subjects
United States. Food and Drug Administration, Cancer treatment, Tumor proteins -- Genetic aspects -- Drug therapy, Tumors -- Drug therapy -- Genetic aspects, Cancer patients -- Drug therapy, Drug approval, Banking, finance and accounting industries, Business
Abstract

CRANBURY, N.J., Oct 13, 2020 (GLOBE NEWSWIRE via COMTEX) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting [...]

Published
2020

7. Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors

Subjects
United States. Food and Drug Administration, Chemotherapy, Tumors -- Drug therapy -- Genetic aspects, Business, international, Law
Abstract

(GlobeNewswire) - Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the Food and Drug Administration (FDA) granted [...]

Published
2020

8. Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors

Subjects
United States. Food and Drug Administration, Chemotherapy, Tumors -- Drug therapy -- Genetic aspects, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Aug 24, 2020 (GLOBE NEWSWIRE via COMTEX) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today [...]

Published
2020

9. Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation

Subjects
United States. Food and Drug Administration, Tumors -- Drug therapy -- Genetic aspects, Epidermal growth factors -- Genetic aspects, Banking, finance and accounting industries, Business
Abstract

CAMBRIDGE, Jul 28, 2020 (GLOBE NEWSWIRE via COMTEX) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results